EMA Authorised: Lunsumio (mosunetuzumab) — Roche Registration GmbH

View source ↗

Summary

The EMA authorises Lunsumio (mosunetuzumab) from Roche Registration GmbH for follicular lymphoma with conditional approval and orphan designation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• LUNSUMIO (mosunetuzumab)

Snippet

Status: Authorised. Therapeutic area: Lymphoma, Follicular. MAH: Roche Registration GmbH. Decision date: 30/06/2026. Conditional approval. Orphan medicine